Page last updated: 2024-11-05

bromodeoxyuridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6035
CHEMBL ID222280
CHEBI ID472552
SCHEMBL ID27755
MeSH IDM0002951

Synonyms (119)

Synonym
MLS002153366
smr001227189
5-bromodesoxyuridine
BDU ,
5-bromo-2'-deoxyuridine ,
budr
5-bromodeoxyuridine
5-bdu
5-bromouracil deoxyriboside
nsc-38297
5-bromouracil-2-deoxyriboside
brdu
bromodeoxyuridine
broxuridine
bromouracil deoxyriboside
EU-0100212
5-bromo-2'-deoxyuridine, >=99% (hplc)
5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
5-bromo-durd
5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
59-14-3
LOPAC0_000212
MLS001055406
5-bromo-2'-deoxyuridine (brdu)
NCGC00090770-01
carbobenzoxy-valyl-alanyl-aspartyl-[o-methyl]-fluoromethylketone
ccris 818
einecs 200-415-9
brn 0030395
broxuridine [inn]
broxuridinum [inn-latin]
c9h11brn2o5
hsdb 7477
5-bromo-2-deoxyuridine
broxuridina [inn-spanish]
5-bromo-2'-deoxyuridine, 97%
5-bromo-2'-deoxyuridine, bioultra, >=99%
NCGC00090770-05
D01763
broxuridine (jan/inn)
MAYBRIDGE4_003385
NCGC00090770-03
NCGC00090770-02
NCGC00175901-01
NCGC00090770-04
B 5002
br-du; 5-bromo-1-(2-deoxy-beta-d-ribofuranosyl)uracil
broxuridina
CHEBI:472552 ,
broxuridinum
B1575 ,
5-bromo-1-(2-deoxy-beta-d-ribofuranosyl)uracil
5-brdu
NCGC00090770-07
CHEMBL222280 ,
HMS1619B05
5-bromo-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
5-bromo-2''-deoxy uridine
cid_6035
bdbm50207303
AKOS001715166
NCGC00090770-06
NCGC00090770-08
HMS3260L05
1-[(4s,2r,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-bromo-1,3-dihydropyrim idine-2,4-dione
broxuridine [inn:jan]
4-24-00-01234 (beilstein handbook reference)
unii-g34n38r2n1
g34n38r2n1 ,
HMS3039G15
tox21_200106
NCGC00257660-01
dtxsid7033105 ,
cas-59-14-3
dtxcid5013105
tox21_111016
CCG-204307
AKOS016015753
LP00212
EPITOPE ID:138105
HG1160
broxuridine [mart.]
broxuridine [hsdb]
broxuridine [mi]
5-bromo-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
broxuridine [who-dd]
broxuridine [jan]
HY-15910
5-bromo-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyridine-2,4(1h,3h)-dione
5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
SCHEMBL27755
NCGC00090770-09
tox21_111016_1
J-700086
tox21_500212
NCGC00260897-01
WOVKYSAHUYNSMH-RRKCRQDMSA-N
5-bromo-2'-deoxy uridine
5-bromo-2'-deoxyuridine(brdu)
(+)-5-bromo-2'-deoxyuridine
HB0979
brdu (5-bromo-2′-deoxyuridine)
mfcd00006529
sr-01000075718
SR-01000075718-1
5-bromo-2'-deoxyuridine, >=99.0% (hplc)
DB12028
STL530083
5-bromo-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-4-hydroxypyrimidin-2(1h)-one
(+)-5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]- pyrimidine-2,4-dione
BCP21681
AKOS037495737
Q419861
AS-11762
SDCCGSBI-0050200.P002
NCGC00090770-14
5-brom-2'-desoxyuridin
EN300-7376709
BP-58665

Research Excerpts

Overview

5-Bromodeoxyuridine (BrdU) is a thymidine analog that affects various biological processes, such as cellular differentiation and cellular senescence. It is a halogenated pyrimidine that incorporates into newly synthesized DNA during the S phase.

ExcerptReferenceRelevance
"Bromodeoxyuridine (BrdU) is a synthetic nucleoside used to detect cellular proliferation. "( Bromodeoxyuridine (BrdU) treatment to measure hepatocellular proliferation does not mask furan-induced gene expression changes in mouse liver.
Recio, L; Webster, AF; Williams, A; Yauk, CL, 2014
)
3.29
"Bromodeoxyuridine (BrdU) is a halogenated pyrimidine that incorporates into newly synthesized DNA during the S phase. "( Bromodeoxyuridine induces senescence in neural stem and progenitor cells.
Caldeira, M; Laywell, ED; Levkoff, LH; Marshall, GP; Reynolds, BA; Ross, HH; Steindler, DA, 2008
)
3.23
"5-Bromodeoxyuridine (BrdU) is a thymidine analog that affects various biological processes, such as cellular differentiation and cellular senescence in cultured mammalian cells."( Identification of genes that affect sensitivity to 5-bromodeoxyuridine in the yeast Saccharomyces cerevisiae.
Ayusawa, D; Fujii, M; Miki, K; Takayama, S, 2010
)
1.17
"5-Bromodeoxyuridine (BrdU) is a thymidine analogue that modulates various biological phenomena such as cellular differentiation and cellular senescence in cultured mammalian cells."( N-terminal short fragment of TUP1 confers resistance to 5-bromodeoxyuridine in the yeast Saccharomyces cerevisiae.
Ayusawa, D; Fujii, M; Miki, K; Nakagawa, Y; Takayama, S, 2011
)
1.17
"Bromodeoxyuridine (BrdU) is a thymidine analog that incorporates DNA of dividing cells during the S-phase of the cell cycle. "( BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation.
Taupin, P, 2007
)
1.78
"Bromodeoxyuridine, which is a thymidin analogue that is incorporated into the DNA of newly formed cells, was administered during 9 days to even out the effects of hormonal fluctuations."( Social isolation increases number of newly proliferated cells in hippocampus in female flinders sensitive line rats.
Bjørnebekk, A; Brené, S; Gruber, SH; Mathé, AA, 2007
)
1.06
"Bromodeoxyuridine (BrdU) is a thymidine analog that is incorporated into cellular DNA in the synthetic phase. "( The correlation of two argyrophilic nucleolar organizer region counting methods with bromodeoxyuridine-labeling index: a study of metastatic tumors of the brain.
Atkinson, EN; Bruner, JM; Connelly, JH; Mourad, WA; Sembera, DL, 1993
)
1.95
"5-Bromodeoxyuridine is a radiosensitizing agent that is currently being evaluated in clinical trials as an adjuvant in the treatment of a variety of cancers. "( The effects of secondary structure and O2 on the formation of direct strand breaks upon UV irradiation of 5-bromodeoxyuridine-containing oligonucleotides.
Chen, T; Cook, GP; Greenberg, MM; Koppisch, AT, 1999
)
1.24
"Bromodeoxyuridine, which is a thymidine analog and is taken into the cells in the synthetic phase, was introduced intraperitoneally 2 hours before the harvest."( The role of serum imbibition for skin grafts.
Fukui, A; Haga, S; Hashimoto, K; Koizumi, M; Maeda, M; Nagano-Tatsumi, K; Nakamura, T; Tamai, S; Yamamoto, H; Yamauchi, T, 1999
)
1.02
"Bromodeoxyuridine (BrdU) is a thymidine analogue which is incorporated into the cells of DNA synthetic phase. "( [Application of bromodeoxyuridine (BrdU) and anti-BrdU monoclonal antibody for the analysis of tumor cell kinetics by flow cytometry].
Kanno, M; Nakamura, S; Takeda, Y, 1992
)
2.07
"Bromodeoxyuridine (BUdR) is a non-radioactive thymidine analogue which is incorporated into DNA during the S-phase of cycling cells."( Cell kinetics evaluation of colorectal tumors after in vivo administration of bromodeoxyuridine.
Bormioli, ML; Di Gregorio, C; Fante, R; Losi, L; Pedroni, M; Petocchi, B; Ponz de Leon, M; Roncucci, L; Sassatelli, R; Scalmati, A, 1992
)
1.23
"5'-Bromodeoxyuridine (BrdU) is a thymidine analogue which can be detected by monoclonal antibodies (MAb). "( Simultaneous immunocytochemical visualization of bromodeoxyuridine and neural tissue antigens.
Del Rio, JA; Soriano, E, 1991
)
1.16
"Bromodeoxyuridine (BUDR) is a thymidine analog that is incorporated into the DNA of proliferating cells. "( Cell proliferation of human leukemia and solid tumors studied with in vivo bromodeoxyuridine and flow cytometry.
Brugnatelli, S; Danova, M; Giordano, M; Mazzini, G; Riccardi, A, 1991
)
1.95
"Bromodeoxyuridine (BUDR) is a non-radioactive thymidine analogue which is incorporated into the DNA of proliferating cells. "( In vivo bromodeoxyuridine incorporation in human gastric cancer: a study on formalin-fixed and paraffin-embedded sections.
Brugnatelli, S; Buttini, R; Danova, M; Dionigi, P; Fiocca, R; Giordano, M; Giordano, P; Girino, M; Riccardi, A; Villani, L, 1988
)
2.15
"Bromodeoxyuridine (BUdR) is a radiosensitizer that can be incorporated into cellular DNA as a substitute for thymidine at the time of DNA synthesis. "( Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors.
Hoshino, T; Kohno, T; Matsuda, T; Matsutani, M; Nagashima, T; Nagayama, I; Sano, K,
)
1.84
"Bromodeoxyuridine (BrdUrd) is a pyrimidine analogue which is incorporated into the DNA of proliferating cells. "( Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry.
Ascari, E; Brugnatelli, S; Danova, M; Dörmer, P; Girino, M; Mazzini, G; McNally, NJ; Riccardi, A; Ucci, G; Wilson, G, 1988
)
1.95
"Bromodeoxyuridine (BUDR) is a thymidine analog which is incorporated into the DNA of proliferating cells. "( Cell kinetics of human brain tumors: in vivo study with bromodeoxyuridine and flow cytometry.
Brugnatelli, S; Butti, G; Buttini, R; Danova, M; Gaetani, P; Mazzini, G; Paoletti, P; Riccardi, A; Ucci, G; Wilson, GD, 1988
)
1.96

Effects

Bromodeoxyuridine (BrdU) has commonly been used for detecting of label-retaining cells (LRCs) It has been compared with a propidium iodide DNA method to detect cells in S phase.

ExcerptReferenceRelevance
"Bromodeoxyuridine (BrdU) has commonly been used for detecting of label-retaining cells (LRCs). "( Distribution of BrdU label-retaining cells in eccrine sweat glands and comparison of the percentage of BrdU-positive cells in eccrine sweat glands and in epidermis in rats.
Chen, L; Fu, X; Li, H; Tang, S; Zhang, M, 2014
)
1.85
"A bromodeoxyuridine method has been compared with a propidium iodide DNA method to detect cells in S phase and CD38-FITC has been compared with CD38-FITC + CD138-FITC and CD38-biotin + streptavidin FITC to identify plasma cells."( The bone marrow plasma cell labeling index by flow cytometry.
Brown, R; Gibson, J; Joshua, D; Pope, B, 1999
)
0.86
"76Br-bromodeoxyuridine has previously been suggested as a PET tracer to characterize proliferation potential. "( Analysis of 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker.
Bergström, M; Fasth, KJ; Gudjonssona, O; Kristjansson, S; Långström, B; Nyberg, G; Wu, F, 2001
)
0.82
"5-bromodeoxyuridine (BUdR) has been shown to induce mutations to 6M resistance in cells of the 237i clone; the rate of induced mutations in some experiments as compared to the rate of spontaneous mutations was 1-2 orders higher."( [A further study of the mutation process in Chinese hamster cells in vitro].
Khalizev, AE; Petrova, ON; Shapiro, NI, 1975
)
0.81

Actions

ExcerptReferenceRelevance
"Bromodeoxyuridine does not enhance the production of these particles."( Effect of bromodeoxyuridine and interferon on cellular and viral functions in human prostatic cells.
Arya, SK; Carter, WA; Chawda, R; Horoszewicz, JS; Job, L, 1979
)
1.38

Treatment

Bromodeoxyuridine (BrdUrd) treatment of the prolactin nonproducing subclone of GH cells (rat pituitary tumor cells) induces amplification of a 20-kilobase DNA fragment including all of the Prolactin gene coding sequences. Bromode Oxyuridine and light treatment of alloreactive T cells generated in vitro was used to demonstrate that DAPCs primed with a synthetic polypeptide antigen (T,G)-A-L can stimulate only HLA class II-compatible T lymphocytes.

ExcerptReferenceRelevance
"Bromodeoxyuridine (BrdUrd) treatment of the prolactin nonproducing subclone of GH cells (rat pituitary tumor cells) induces amplification of a 20-kilobase DNA fragment including all of the prolactin gene coding sequences. "( Identification of DNA sequence responsible for 5-bromodeoxyuridine-induced gene amplification.
Biswas, DK; Hartigan, JA; Pichler, MH, 1984
)
1.96
"5-Bromodeoxyuridine (BrdU) treatment of chicken and mouse myoblasts reduces the expression of CMD1 and MyoD1, respectively, and may explain how this thymidine analog inhibits myogenesis and the activity of transfected muscle-specific promoters in BrdU-treated myoblasts."( An avian muscle factor related to MyoD1 activates muscle-specific promoters in nonmuscle cells of different germ-layer origin and in BrdU-treated myoblasts.
Dechesne, CA; Eldridge, J; Lin, ZY; Paterson, BM, 1989
)
0.84
"Bromodeoxyuridine and light treatment of alloreactive T cells generated in vitro was used to demonstrate that DAPCs primed with a synthetic polypeptide antigen (T,G)-A-L can stimulate only HLA class II-compatible T lymphocytes."( Antigen-presenting cells in human decidual tissue.
Brautbar, C; Mor-Yosef, S; Mozes, E; Oksenberg, JR; Persitz, E; Schenker, Y, 1986
)
0.99
"Untreated or bromodeoxyuridine (BrdUrd)-treated Friend erythroleukaemia (EL) cells from 15- and 72-h-cultures were harvested and the mitochondria were isolated by homogenization and differential centrifugation. "( Effects of 5-bromo-2'-deoxyuridine on Friend erythroleukaemia cells. II. Oxidative metabolism and enzyme content of whole cells and isolated mitochondria.
Walter, RJ, 1981
)
0.63
"Treatment of bromodeoxyuridine-suppressed cultures at confluence with 1-methyl-3-isobutylxanthine, a promoter of the adipose conversion, results in differentiation of the fibroblasts into adipose cells but the extent of the conversion is less than that seen in cultures not treated with bromodeoxyuridine."( Differentiation of 3T3-L2 fibroblasts into adipose cells in bromodeoxyuridine-suppressed cultures.
Russell, TR, 1979
)
0.85
"Treatment with bromodeoxyuridine (50 microgram/ml for 24 h) resulted in induction of XC-positive NB-tropic virus, although only a small fraction of the cells released virus (less than 0.1% after 48 h)."( Highly inducible cell lines derived from mice genetically transmitting the Moloney murine leukemia virus genome.
Bacheler, L; Fan, H; Jaenisch, R, 1979
)
0.6

Toxicity

ExcerptReferenceRelevance
"The toxic action of misonidazole towards hypoxic mammalian cells has been shown to be a function of serum concentration, with higher serum concentrations enhancing the toxic effect."( Some factors affecting the specific toxicity of misonidazole towards hypoxic mammalian cells.
Gray, P; Stratford, IJ, 1978
)
0.26
" All of the HUr lines showed increased resistance to the toxic effects of BrdU."( Resistance to bromodeoxyuridine mutagenesis and toxicity in mammalian cells selected for resistance to hydroxyurea.
Davidson, RL; Kaufman, ER, 1979
)
0.62
" Toxicity of the compounds was shown to be exerted during DNA replication but their toxic action may also be due to membrane damage and inhibition of cell metabolism."( Cytotoxicity of a selected series of substituted phenols towards cultured melanoma cells.
Menko, W; Pavel, S; Peters, K; Riley, PA; Smit, NP; Westerhof, W, 1992
)
0.28
" Histopathologically, rats fed 1,000 ppm harman or norharman, but not 500 ppm, demonstrated focal toxic renal degenerative/necrotic and regenerative lesions in proximal, distal, and collecting tubules."( Dose-dependent renal tubular toxicity of harman and norharman in male F344 rats.
Asakawa, E; Hagiwara, A; Hirose, M; Ito, N; Kurata, Y; Sano, M, 1992
)
0.28
" Female rats were much less susceptible to the toxic effects of EQ than males of the same age."( Degree of ethoxyquin-induced nephrotoxicity in rat is dependent on age and sex.
Carthew, P; Green, JA; Manson, MM; Wright, BJ, 1992
)
0.28
" These findings might suggest that a major role of thymic phagocytic cells is the supply of pyrimidine nucleosides to thymocytes resulting in the maintenance of proliferation and protection of at least some thymic blasts from the toxic effects of dGTP accumulation."( Regulation of thymocyte proliferation and survival by deoxynucleosides. Deoxycytidine produced by thymic accessory cells protects thymocytes from deoxyguanosine toxicity and stimulates their spontaneous proliferation.
Papiernik, M; Penit, C, 1986
)
0.27
"A V79 Chinese hamster fibroblast cell line selected for resistance to the toxic effects of 5-fluorouracil (Kaufman, 1984b) was found to be cross-resistant to the toxic effects of the thymidine analog 5-bromodeoxyuridine (BrdUrd)."( Altered CTP synthetase activity confers resistance to 5-bromodeoxyuridine toxicity and mutagenesis.
Kaufman, ER, 1986
)
0.71
" Also, cell morphology showed early toxic changes, such as cytoplasmic vacuolization and cell shrinking, and it should be included with such toxicity evaluations."( Comparison of cell proliferation and toxicity assays using two cationic liposomes.
Jääskeläinen, I; Lappalainen, K; Syrjänen, K; Syrjänen, S; Urtti, A, 1994
)
0.29
" Nasal passages were also examined for toxic responses."( The toxicity of 1-week exposures to inhaled chloroform in female B6C3F1 mice and male F-344 rats.
Butterworth, BE; Larson, JL; Méry, S; Morgan, KT; Wolf, DC, 1994
)
0.29
"Quinolone antibacterial agents have adverse effects on the musculoskeletal system in humans, consisting mainly of myalgia and arthralgia, and additionally of tendon disorders and rhabdomyolysis."( Toxic effects of quinolone antibacterial agents on the musculoskeletal system in juvenile rats.
Kashida, Y; Kato, M,
)
0.13
" This pattern of toxicity is compatible with a direct toxic effect of CyA on cells of the proximal tubule, with predominant morphological destruction of the cells, with concomitant proximal tubular dysfunction, and a functional alteration in cells of the distal tubule associated with increased paracellular resistance, which may lead to solute and water loss."( Tubular toxicity of cyclosporine A and the influence of endothelin-1 in renal cell culture models (LLC-PK1 and MDCK).
Brandis, M; Kölmel, C; Krämer, F; Mesa, H; Wiegele, G; Zimmerhackl, LB, 1997
)
0.3
" The parallel study of DNA synthesis and cell protein content suggests that the toxic damage produced by silver in different phases of the cell cycle may lead to destruction of the entire cell population and therefore hinder the tissue regeneration process."( Study of cytotoxicity mechanisms of silver nitrate in human dermal fibroblasts.
Domínguez, C; Hidalgo, E, 1998
)
0.3
"The usefulness of the lymphocyte transformation test (LTT) for the analysis of adverse reactions to antituberculous drugs was evaluated."( Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
Greinert, U; Müller-Quernheim, J; Schlaak, M; Schreiber, J; Zissel, G, 1999
)
0.3
" At the same toxin concentrations used in the BrdU bioassay, only T-2 and HT-2 were toxic enough to obtain IC50 values using the MTT bioassay."( Cytotoxicity of four trichothecenes evaluated by three colorimetric bioassays.
Lindberg, JE; Lundh, T; Pettersson, H; Widestrand, J, 1999
)
0.3
" Trichothecene-free samples of wheat, wheat bran and barley had no toxic effect on the 3T3 cells at sample concentrations up to 400 mg/ml cell culture medium while a few oat samples had an inhibiting effect on the DNA-synthesis."( A rapid and sensitive cytotoxicity screening assay for trichothecenes in cereal samples.
Lindberg, JE; Lundh, T; Pettersson, H; Widestrand, J, 2003
)
0.32
" 3-AcDON was less toxic than DON and 15-AcDON."( Comparative cytotoxicity of deoxynivalenol, nivalenol, their acetylated derivatives and de-epoxy metabolites.
Lundh, T; Pettersson, H; Sundstøl Eriksen, G, 2004
)
0.32
"Experiments on rat liver slices demonstrated the differential hepatobiliary toxic potency of two anticancer agents, geldanamycin (GEL) and 17-allylaminogeldanamycin (17-AAG), over a 5-day period."( In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin using dog liver slices.
Amin, K; Behrsing, H; Ip, C; Jimenez, L; Tyson, C, 2005
)
0.33
" In both assays, MeHgCl was the most toxic substance."( Cytotoxicity of dental composite (co)monomers and the amalgam component Hg(2+) in human gingival fibroblasts.
Esters, M; Hickel, R; Kehe, K; Kleinsasser, N; Reichl, FX; Seiss, M; Simon, S, 2006
)
0.33
" As determined by Toxilight-cytotoxicity assay, the drug was only toxic to the cancer cells at 100 microM."( Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells.
Chiu, LC; Ooi, VE; Tong, KF, 2005
)
0.33
" Treating these cultures with caspase-3 inhibitor z-VAD-fmk did not protect the cells from MbetaCD toxic effects."( Characterization of methyl-beta-cyclodextrin toxicity in NGF-differentiated PC12 cell death.
Almaguel, FG; Bu, L; De Leon, M; Liu, JW; Padilla, A; Ulloth, JE, 2007
)
0.34
" We hypothesize that soluble blood constituents have an adverse effect on the proliferation of cultured rat subventricular zone (SVZ) cells and the proliferation, migration, and differentiation of oligodendrocyte progenitor cells (OPC)."( Toxic effect of blood components on perinatal rat subventricular zone cells and oligodendrocyte precursor cell proliferation, differentiation and migration in culture.
Balasubramaniam, J; Del Bigio, MR; Frost, EE; Juliet, PA, 2009
)
0.35
"Bevacizumab was not toxic to RGC-5 cells in the tested concentrations."( In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line.
Chalam, KV; Sharma, RK, 2009
)
0.35
" It is known that mTHPC possesses a significant phototoxicity against a variety of human cancer cells in vitro but also exhibits dark toxicity and can cause adverse effects (especially skin photosensitization)."( Comparison of intracellular accumulation and cytotoxicity of free mTHPC and mTHPC-loaded PLGA nanoparticles in human colon carcinoma cells.
Engel, A; Knobloch, T; Langer, K; Löw, K; von Briesen, H; Wagner, S; Wiehe, A, 2011
)
0.37
"Phenazine was recently identified as a drinking water disinfection byproduct (DBP), but little is known of its toxic effects."( Cytotoxicity and genotoxicity of phenazine in two human cell lines.
Li, XF; McGuigan, CF, 2014
)
0.4
" Our results demonstrate that elevated concentrations (similar to manufacturers suggested concentration; >5-10 μM) of EdU treatment were toxic to the cell cultures, particularly in cells with a defect in homologous recombination repair."( Evaluating the Genotoxic and Cytotoxic Effects of Thymidine Analogs, 5-Ethynyl-2'-Deoxyuridine and 5-Bromo-2'-Deoxyurdine to Mammalian Cells.
Allum, AJ; Froning, CE; Haskins, AH; Haskins, JS; Kato, TA; Maeda, J; Su, C; Walsh, KD, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells."( Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989
)
0.28
" In all tissues, DNA incorporation showed saturating effects as plasma BrdUrd concentration was increased and, BrdUrd incorporation as a function of plasma concentration could be fitted to a Langmuir-like equation generating tissue-specific pharmacodynamic parameters: Imax for percentage thymine replacement at infinite plasma BrdUrd concentrations, and C50 for the arterial BrdUrd concentration generating incorporation that is Imax/2."( Tissue-specific pharmacodynamics of 5-bromo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.
Averill, DR; Johnson, NJ; Knol, JA; Maybaum, J; Preiskorn, D; Smith, P; Stetson, PL; Wagner, JG; Wollner, IS; Yang, ZM, 1988
)
0.27
" EDU was eliminated from blood with a half-life of 35."( Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
Cheraghali, AM; Knaus, EE; Kumar, R; Wiebe, LI, 1995
)
0.29
" thymidine or TdR, and bromodeoxyuridine or BrdU) and expression of proliferating cell nuclear antigen (PCNA), as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors."( Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors.
Au, JL; Gan, Y; Weaver, JR, 1998
)
0.61
" With the recent publication of human pharmacokinetic data from clinical studies, we now know the achievable levels and range of AZD6244 exposure in humans."( Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.
Denton, CL; Gustafson, DL, 2011
)
0.37
" Additionally, pharmacodynamic endpoints such as tumor proliferation and ERK phosphorylation were analyzed at various time points after the last dose."( Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.
Denton, CL; Gustafson, DL, 2011
)
0.37
" Pharmacokinetic analyses of intravenous allopregnanolone in rabbit and mouse indicated that peak plasma and brain levels (3-fold brain/plasma ratios) at 5min were sufficient to activate neuroregenerative responses at sub-sedative doses."( Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease.
Bauer, G; Brinton, RD; Irwin, RW; Loya, CM; Rodgers, KE; Rogawski, MA; Salituro, FG; Solinsky, CM, 2015
)
0.42
" Informed by these measurements, we built a pharmacokinetic model that quantitatively predicts microbiome contributions to systemic drug and metabolite exposure, as a function of bioavailability, host and microbial drug-metabolizing activity, drug and metabolite absorption, and intestinal transit kinetics."( Separating host and microbiome contributions to drug pharmacokinetics and toxicity.
Goodman, AL; Wegmann, R; Zimmermann, M; Zimmermann-Kogadeeva, M, 2019
)
0.51

Compound-Compound Interactions

RDEA119/BAY 869766 alone or in combination with rapamycin showed significant growth inhibition in all the 3 models. A significant decrease in the percentage of cells in S-phase, accompanied by a large decrease in bromodeoxyuridine labelling and cell cycle arrest.

ExcerptReferenceRelevance
" rhGM-CSF (250 micrograms/m2/d, continuous intravenous infusion) was administered in 18 pts suffering from de novo AML in combination with standard induction chemotherapy (3 + 7 = daunorubicin 45 mg/m2 days 1 through 3, cytosine-arabinoside [Ara-C] 200 mg/m2 continuous infusion days 1 through 7)."( Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
Andreeff, M; Bettelheim, P; Gorischek, C; Haas, O; Haimi, J; Muhm, M; Sillaber, C; Tafuri, A; Valent, P; Vieder, L, 1991
)
0.28
"The antiviral activity and cytotoxicity of (E)-5-(2-bromovinyl)-2'-deoxycytidine (BrVdCyd) against herpes simplex virus type 1 (HSV-1), singly and in combination with deaminase inhibitors was determined using rabbit kidney (RK-13), HEP-2, BHK-21 and VERO cells."( Antiherpes virus activity and effect on deoxyribonucleoside triphosphate pools of (E)-5-(2-bromovinyl)-2'-deoxycytidine in combination with deaminase inhibitors.
Aduma, PJ; De Clercq, E; Gupta, SV, 1990
)
0.28
"Since 1984, a new method for the intraarterial administration of antineoplastic drugs, termed "superselective intraarterial chemotherapy," has been used in combination with simultaneous irradiation in the treatment of 49 patients with squamous cell carcinoma of the head and neck."( Superselective intraarterial chemotherapy in combination with irradiation: preliminary report.
Hattori, T; Kubo, M; Sakakura, K; Sakakura, Y; Shimizu, T; Yamaguchi, N,
)
0.13
"Sister chromatid exchange (SCE) induced by Indigo carmine (secondary amine containing dye), Fast green FCF (tertiary amine containing dye) and nitrite singly and in combination with nitrite were carried out in vivo in mice following acute exposure."( Sister chromatid exchange induced by secondary and tertiary amine containing dyes and in combination with nitrite in vivo in mice.
Giri, AK; Mukherjee, A, 1990
)
0.28
"Since 1984, a new method for intra-arterial administration of anti-cancer drug and radiosensitizer, named 'superselective continuous intra-arterial infusion therapy' has been used in combination with simultaneous irradiation, for the treatment of 67 patients with the head and neck tumors."( [Continuous superselective intra-arterial infusion with BUdR and 5 FU in combination with radiotherapy in the treatment of head and neck tumors].
Hattori, T; Hirano, T; Murata, M; Nakagawa, T; Sakakura, Y; Tashiro, T; Toyota, S; Yamaguchi, N, 1988
)
0.27
"The sensitivity of varicella zoster virus (VZV) strain Ellen to acyclovir in combination with other antiherpetic agents in vitro has been examined by the plaque-reduction and infectious center assay methods."( Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro.
Biron, KK; Elion, GB, 1982
)
0.26
"In order to demonstrate the existence of proliferating activity in hair follicular melanocytes during the early and anagen III stages, immunocytochemistry for bromodeoxyuridine (BrdU) incorporated in the nuclei of the melanocytes for 1 hr was undertaken at the light and electron microscopic levels in combination with DOPA reaction cytochemistry."( Proliferating activity of the hair follicular melanocytes at the early and anagen III stages in the hair growth cycle: detection by immunocytochemistry for bromodeoxyuridine combined with DOPA reaction cytochemistry.
Morimoto, Y; Saga, K; Sugiyama, S; Takahashi, M, 1995
)
0.69
" A simple procedure for the detection of TGr human peripheral blood lymphocytes was developed in our laboratory, using whole blood culturing and 5-bromodeoxyuridine (BrdU) labeling in combination with immunocytochemical staining."( Detection of 6-thioguanine-resistant human peripheral blood lymphocytes using 5-bromodeoxyuridine labeling in combination with immunocytochemical staining.
Albering, H; Hageman, G; Kleinjans, J; Stierum, R; Welle, I, 1993
)
0.71
"The effects of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) on mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene (DMBA) were investigated in rats."( 1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats.
Kudo, H; Maemura, M; Mitamura, T; Nakayama, T; Sakamoto, S; Sassa, S; Suzuki, S; Yoshimura, S, 1996
)
0.29
"To elucidate the relationship between follicular growth and granulosa cell kinetics, ovarian histology was examined in mice treated with 5-bromo-2'-deoxyuridine (BrdU) or in combination with colchicine."( Granulosa cell kinetics examined by bromodeoxyuridine in combination with colchicine in the mouse ovarian follicles.
Matsumoto, H; Mori, T; Shinohara, Y,
)
0.41
"To evaluate an intracranial polymer implant containing bromodeoxyuridine (BrdUrd) and N-(phosphonacetyl)-L-aspartic acid (PALA) in combination with external beam radiotherapy (EBRT) in the treatment of a rat glioma."( Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy.
Lehnert, S; Li, Y; Owusu, A, 2004
)
0.57
"In tissue culture experiments, C6 cells were refractory to radiosensitization by BrdUrd even when the thymidine analog was combined with a biomodulator intended to reduce de novo thymidine synthesis."( Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy.
Lehnert, S; Li, Y; Owusu, A, 2004
)
0.32
"To evaluate the usefulness of continuous administration of hypoxic cytotoxins in terms of targeting acute hypoxia in solid tumours and the significance of combination with mild temperature hyperthermia (MTH) (40 degrees C, 60 min), the cytotoxic effects of singly or continuously administered tirapazamine (TPZ) and TX-402 were examined in combination with or without MTH in vivo."( The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Suzuki, M; Uto, Y, 2005
)
0.33
"We clarified the usefulness of the continuous administration of tirapazamine (TPZ) in combination with reduced dose-rate irradiation (RDRI) using gamma-rays or reactor thermal neutrons."( The usefulness of a continuous administration of tirapazamine combined with reduced dose-rate irradiation using {gamma}-rays or reactor thermal neutrons.
Hori, H; Kinashi, Y; Maruhashi, A; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Sakurai, Y; Suzuki, M; Uto, Y, 2006
)
0.33
" Importantly, neu-specific antibody responses were restored only when AIT was combined with the depletion of MDSC."( Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.
Bear, HD; Feldmesser, M; Graham, L; Kmieciak, M; Manjili, MH; Morales, JK, 2009
)
0.35
" The effects of RDEA119/BAY 869766 as a single agent and in combination with rapamycin were studied in 3 early passage primary pancreatic cancer xenografts, OCIP19, 21, and 23, grown orthotopically."( Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
Chang, Q; Chapman, MS; Hedley, DW; Miner, JN, 2010
)
0.36
"RDEA119/BAY 869766 alone or in combination with rapamycin showed significant growth inhibition in all the 3 models, with a significant decrease in the percentage of cells in S-phase, accompanied by a large decrease in bromodeoxyuridine labelling and cell cycle arrest predominantly in G1."( Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
Chang, Q; Chapman, MS; Hedley, DW; Miner, JN, 2010
)
0.55
" Moreover, the cells expressing Dm-dNKmut exhibited increased sensitivity in combination with BVDU, with induction of apoptosis in vitro and in vivo."( Potent anticancer effects of lentivirus encoding a Drosophila melanogaster deoxyribonucleoside kinase mutant combined with brivudine.
Gu, M; Ma, S; Zhang, NQ; Zhao, L; Zheng, XY, 2012
)
0.38
" The cytotoxicity and bystander effects of Dm‑dNK combined with cytotoxic nucleoside analogs were both observed in Dm‑dNK+ keloid fibroblasts."( Efficacy of lentivirus‑mediated Drosophila melanogaster deoxyribonucleoside kinase combined with (E)‑5‑(2‑bromovinyl)‑2'‑deoxyuridine or 1‑β‑D‑arabinofuranosylthymine therapy in human keloid fibroblasts.
Gu, M; Jiang, H; Sun, Y; Zheng, X, 2018
)
0.48
" In summary, drilling through the growth plate combined with ADSC and BMP-2 treatments induced new bone formation and protected the femoral head epiphysis from collapsing in a juvenile rabbit model of femoral head epiphyseal ischemic necrosis."( Drilling Combined with Adipose-derived Stem Cells and Bone Morphogenetic Protein-2 to Treat Femoral Head Epiphyseal Necrosis in Juvenile Rabbits.
Ba, HL; Cao, X; He, JS; He, RZ; Peng, C; Tu, B; Wang, ZL; Wu, S; Xia, HS; Xiong, K, 2018
)
0.48
"In the current report we present the case of a patient experiencing a life-threatening drug-drug interaction involving the concurrent administration of capecitabine and brivudine."( A life-threatening drug-drug interaction between capecitabine and brivudine in a patient with metastatic breast cancer.
Antoniadou, V; Diamantopoulos, P; Gogas, H; Halioti, A; Mantzourani, M; Papaxoinis, G; Tsifi, A,
)
0.13
" Here, we investigated the effect of multifactor intervention, voluntary wheel exercise, and involuntary treadmill running in combination with acousto-optic stimulation, on adult neurogenesis and behavioral phenotypes in a mouse model of AD."( Effects of Involuntary and Voluntary Exercise in Combination with Acousto-Optic Stimulation on Adult Neurogenesis in an Alzheimer's Mouse Model.
Gao, JY; Guo, JJ; Li, GY; Li, LP; Li, WY; Lin, SY; Liu, ZT; Ma, YT; Pan, ST; Shen, W; Wang, QW; Xiao, B; Xie, K, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" The findings point to a need for further studies on the possible function of peptides derived from milk proteins as orally bioavailable immunopotentiatory compounds."( Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins.
Kayser, H; Meisel, H, 1996
)
0.29
" In mouse, rat, and monkey systems, SCH 66336 has excellent oral bioavailability and pharmacokinetic properties."( Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Bishop, WR; Bryant, MS; Catino, JJ; Chen, J; Dell, J; Doll, RJ; Ferrari, E; Girijavallabhan, VM; Korfmacher, WA; Lee, S; Lin, CC; Lipari, P; Liu, M; Malkowski, M; Mallams, AK; Nielsen, L; Njoroge, FG; Nomeir, AA; Prioli, N; Remiszewski, S; Sinha, D; Syed, J; Taveras, AG; Wang, L; Yaremko, B, 1998
)
0.3
" However, the clinical use of these proteic factors is still restricted, and brings about undesirable consequences, including adverse side effects, and bioavailability and stability difficulties."( Neurotrophic activity of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one in cultured central nervous system neurons.
Coowar, D; Duportail, G; Girlanda-Junges, C; Gonzalez de Aguilar, JL; Loeffler, JP; Luu, B, 2001
)
0.31
" One limitation to its use is the necessity of co-injecting cimetidine to increase its bioavailability and hence its sensitivity for PET detection."( Use of 5-[(76)Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model.
Bergström, M; Borbath, I; Grégoire, V; Långström, B; Laryea, D; Pauwels, S, 2002
)
0.31
"8 GHz (217 Hz amplitude-modulated) with the output power in the specific absorption rate (SAR) of 1, 2 and 3 W/kg."( Effects of 1.8 GHz radiofrequency field on DNA damage and expression of heat shock protein 70 in human lens epithelial cells.
Baohong, W; Deqiang, L; Huajun, H; Jianling, L; Kaijun, W; Lixia, S; Wei, W; Wei, Z; Xiangwei, G; Yao, K, 2006
)
0.33
" Experiments using a saturating dose of BrdU suggested BrdU bioavailability is less than 15 min, notably shorter than in the developing mouse brain."( Determination of key aspects of precursor cell proliferation, cell cycle length and kinetics in the adult mouse subgranular zone.
Eisch, AJ; Harburg, GC; Mandyam, CD, 2007
)
0.34
" After occlusion, autologous bone marrow cells alone or in combination with agents to improve NO bioavailability were administered intraarterially."( Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia.
Baker, AH; Casamassimi, A; de Nigris, F; Ignarro, LJ; Lanza, A; Lerman, LO; Napoli, C; Rienzo, M; Schiano, C; Sica, V; Williams-Ignarro, S; Work, LM, 2007
)
0.34
" Exposure of MCF7 cells to either single (837 MHz) or combined (837 and 1950 MHz) RF radiation was conducted at specific absorption rate values of 4 W/kg for 1 h."( Effects of combined radiofrequency radiation exposure on the cell cycle and its regulatory proteins.
Han, NK; Kim, BC; Kim, N; Kim, T; Lee, JS; Lee, KY; Lee, YS; Pack, JK; Yun, JH, 2011
)
0.37
" This may be due to increased scavenging of NO in the SHR, leading to diminished bioavailability of NO."( Nitric oxide is less effective at inhibiting neointimal hyperplasia in spontaneously hypertensive rats.
Kibbe, MR; Lee, VR; Martinez, J; Tsihlis, ND; Vavra, AK, 2013
)
0.39
"To study the effects of BAY-84-7296, a novel orally bioavailable inhibitor of mitochondrial complex I and hypoxia-inducible factor 1 (HIF-1) activity, on hypoxia, microenvironment, and radiation response of tumors."( Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation.
Baumann, M; Brüchner, K; Gurtner, K; Helbig, L; Hess-Stumpp, H; Koi, L; Pruschy, M; Unterschemmann, K; Yaromina, A; Zips, D, 2014
)
0.4
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" To date, using a variety of methods, only the bioavailability time of tritiated thymidine and 5-bromo-2'-deoxyuridine (BrdU) have been evaluated."( The bioavailability time of commonly used thymidine analogues after intraperitoneal delivery in mice: labeling kinetics in vivo and clearance from blood serum.
Belousov, VV; Enikolopov, GN; Maltsev, DI; Mellanson, KA; Podgorny, OV, 2022
)
0.72

Dosage Studied

Bromodeoxyuridine (BrdU), a non-radioactive thymidine analogue, was administered to 15 cattle at a dosage of 1-10 mg/kg intravenously or intraperitoneally to demonstrate S-phase cells in the tissues. A dose-response effect on the number of bromode Oxyuridine-labeled endothelial cells located in the granule cell layer, hilus, and molecular layer was noted.

ExcerptRelevanceReference
"The survival curve of colony-forming ability of Chinese hamster wg3h cells has been compared with the dose-response curve for the expression of an active thymidine kinase (TK) gene from these cells."( Rescue of marker phenotypes: effects of BUdR sensitization, hypoxia and high LET.
Boyle, JM, 1979
)
0.26
" Dose-response studies showed that the level of viral induction by UV was dependent upon cellular UV exposure."( Ultraviolet radiation induction of endogenous murine type C virus.
Brewer, PP; Hellman, KB, 1979
)
0.26
" Different dosage regimens may have advantages and are discussed."( The long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts.
Grierson, I; Hitchings, RA; Khaw, PT; Porter, A; Rice, NS; Ward, S, 1992
)
0.28
" A dose-response experiment shows that it does not, but remains approximately constant at about 12%, even in the unirradiated control."( Revell revisited.
Harvey, AN; Savage, JR,
)
0.13
" Dose-response curves of micronucleus (MN) frequency appearing in non-S-phase cells were also determined by excluding S-phase cells with immunofluorescence staining to 5-bromo-2'-deoxyuridine (BUdR)."( Use of the micronucleus assay for the selective detection of radiosensitivity in BUdR-unincorporated cells after pulse-labelling of exponentially growing tumour cells.
Abe, M; Fushiki, M; Masunaga, S; Ono, K; Wandl, EO, 1990
)
0.28
" Comparison to chromosome-aberration studies demonstrates the suitability of this method to screen quickly for adequate dosing of a cytotoxic substance and also gives information on the appropriate preparation interval."( Flow-cytometric cell-cycle analysis of Chinese hamster cells following exposure to cytotoxicants.
Fertig, G; Miltenburger, HG, 1989
)
0.28
" Total dosage of the radiation was 50-60 Grey for each case."( [A trial of ACNU and radiation therapy with sensitizing agents for malignant gliomas].
Hayashi, M; Ishii, H; Ishii, Y; Kawano, H; Nakatsugawa, S; Satoh, K, 1989
)
0.28
" CsH was observed to reduce both the number and DNA synthesis of EK in a statistically significant manner at the dosage of 5 micrograms/ml after 24, 48 and 72 h in culture."( Nonimmunosuppressive ciclosporin H inhibits the growth and DNA synthesis of cultured normal human epidermal keratinocytes.
Castells-Rodellas, A; Faure, M; Haftek, M; Kanitakis, J; Ramirez-Bosca, A; Thivolet, J, 1989
)
0.28
" These results confirm that, in the ZZ male/ZW female sex-determining system of birds, dosage compensation for Z-linked genes does not occur by inactivation of one of the two Z chromosomes in the homogametic male."( Chromosome banding and DNA replication patterns in bird karyotypes.
Enderle, E; Schempp, W; Schindler, D; Schmid, M, 1989
)
0.28
" Since BrdUrd is not radioactive and is nontoxic at the dosage used, these techniques, together with the histopathological diagnosis, may help to predict the biological malignancy of individual tumors."( Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine.
Hoshino, T; Levin, EM; Levin, VA; Murovic, J; Nagashima, T; Rupp, SM, 1985
)
0.52
" At the end of the dosing period, 4 dogs/sex/dosage were sacrificed and complete gross and microscopic examinations performed."( The chronic toxicity of bromovinyldeoxyuridine in beagle dogs.
Chengelis, CP; Dickie, BC; Port, CD, 1988
)
0.27
" These results are considered to be useful informations for determining the optimal dosage of the antineoplastic agent against the brain tumor and developing the effective combination chemotherapy."( [Effect of ACNU against experimental brain tumor--immunohistochemical study using anti-BrdU monoclonal antibody].
Arita, N; Hayakawa, T; Izumoto, S; Mogami, H; Nagatani, M; Oku, Y; Tzuu-Yuan, H; Ushio, Y; Yoshimine, T, 1988
)
0.27
" Methyl methanesulfonate (MMS) (10 microliters) was applied to the anal lips of day-old chicks to study dose-response kinetics for mutagen targeting to DNA of dividing B-lymphocytes in the bursa."( Targeting of chemical mutagens to differentiating B-lymphocytes in vivo: detection by direct DNA labeling and sister chromatid exchange induction.
Bloom, SE; Dietert, RR; Nanna, UC, 1987
)
0.27
" In pursuit of this goal, we examined the ability of foxhounds with surgically implanted hepatic arterial (HA) delivery systems to tolerate a clinically relevant dosage of HA yttrium-90 (Y-90) by microsphere administration either alone or preceded by a 28-day constant HA infusion of either 5-bromo-2'-deoxyuridine (BUDR) or a control solution."( Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs.
Andrews, JC; Chrisp, CE; Ensminger, WD; Juni, JE; Knutsen, CA; Stetson, PL; Tuscan, MJ; Ullrich, KA; Wollner, IS, 1987
)
0.49
" This dosage of AF-B1 administered to 6-day embryos was found to increase the incidence of sister chromatid exchanges in blood cells approximately fivefold above the baseline observed in solvent controls."( Embryonic exposure to aflatoxin-B1: mutagenicity and influence on development and immunity.
Bloom, SE; Dietert, RR; Nanna, UC; Qureshi, MA, 1985
)
0.27
" Results showed that the optimal treatment times at which the agents could most efficiently produce SCEs were different for MMC and 4NQO, and that the dose-response curves tended to 'bend down' at very high doses; that is, treatments with very high doses induced smaller than expected numbers of SCEs."( Sister-chromatid exchanges and cell-cycle kinetics in human lymphocyte cultures exposed to alkylating mutagens: apparent deformity in dose-response relationships.
Koizumi, A; Morimoto, K; Sato-Mizuno, M,
)
0.13
" The results of gene dosage studies using (1) a histochemical stain to measure X-linked glucose-6-phosphate dehydrogenase (G6PD) activity in single cells and (2) cellulose acetate electrophoresis of G6PD activity in cell extracts also indicated that both Xs in these strains were genetically active."( Human X chromosomes: synchrony of DNA replication in diploid and triploid fibroblasts with multiple active or inactive X chromosomes.
Breg, WR; Willard, HF, 1980
)
0.26
" The effects of this procedure were analyzed by irradiating single metaphases under the microscope, thus allowing precise dosage of radiation."( Rapid irradiation procedure for obtaining permanent differential staining of sister chromatids and aspects of its underlying mechanism.
Buys, CH; Osinga, J; Stienstra, S, 1981
)
0.26
" The frequency of TGr mutations increased linearly with the number of EMS treatments whereas the yield of BrdUrdr mutations showed a curvilinear dose-response curve."( Mutations resistant to bromodeoxyuridine in mouse lymphoma cells selected by repeated exposure to EMS. Characteristics of phenotypic instability and reversion to HAT resistance by 5-azacytidine.
Nakamura, N; Okada, S, 1983
)
0.58
" Fibroblast cultures from 10 retarded males expressed fra(X) in a dose-response relationship to increasing concentrations of FUdR."( Cytogenetic investigations in mentally retarded and normal males from 14 families with the fragile site at Xq28. Results of folic acid treatment on fra(X) expression.
Nielsen, KB; Tommerup, N, 1984
)
0.27
" Also, dose-response curves have been obtained for several carcinogens administered by ip injection."( Development of rodent peripheral blood lymphocyte culture systems to detect cytogenetic damage in vivo.
Erexson, GL; Kligerman, AD; Wilmer, JL, 1984
)
0.27
" No toxic side-effects could be attributed to the drug at the dosage used."( Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients.
De Clercq, E; Wildiers, J, 1984
)
0.27
"Previous biochemical studies have suggested that both X chromosomes produce gene products when cells of the LT-1 teratocarcinoma stem cell line are maintained in the undifferentiated state, and that dosage compensation, the biochemical manifestation of X inactivation, occurs when the cells are induced to differentiate in vitro (Martin et al."( Studies of the temporal relationship between the cytogenetic and biochemical manifestations of X-chromosome inactivation during the differentiation of LT-1 teratocarcinoma stem cells.
Martin, GR; Takagi, N, 1984
)
0.27
" The resulting dose-response relationship for dicentric yield was described by the quadratic equation Y = aD + bD2."( X-ray-induced dicentric yields in lymphocytes of the teleost, Umbra limi.
Etoh, H; Suyama, I, 1983
)
0.27
" These results support the assumption that there is no dosage compensation for Z-linked or X-linked genes by the sex chromosome inactivation mechanism in the sex chromosomes of Amphibia."( Chromosome banding in Amphibia. VI. BrdU-replication patterns in anura and demonstration of XX/XY sex chromosomes in Rana esculenta.
Schempp, W; Schmid, M, 1981
)
0.26
", day 0 or 2 (or day 4, if BVDU was administered subcutaneously) postinfection, at a dosage of 80 mg/kg per day or higher."( Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.
de Clercq, E; Sim, IS; Zhang, ZX, 1982
)
0.26
" Drosophila melanogaster has a comparable system of dosage compensation."( Insect sex chromosomes. VI. A presumptive hyperactivation of the male X chromosome in Acheta domesticus (L.).
Ali, S; Rao, SR, 1982
)
0.26
" These data indicate that (a) dose-response curves for ANIT-induced bile duct obstruction and BEC hyperplasia are similar; (b) ANIT-induced BEC proliferation and bile duct obstruction precedes BEC hyperplasia; (c) BEC proliferation occurred at doses/timepoints associated with BEC damage and bile duct obstruction; and (d) once ANIT-induced bile duct obstruction occurs, the spatial and temporal aspects of BEC proliferation are comparable to those following biliary obstruction induced by bile duct ligation."( Biliary epithelial cell proliferation following alpha-naphthylisothiocyanate (ANIT) treatment: relationship to bile duct obstruction.
DeNicola, DB; Dulik, DM; Goldstein, RS; Kossor, DC; Leonard, TB; Meunier, PC; Ngo, W, 1995
)
0.29
"The therapeutic efficacy of cell cycle phase-specific drugs can be improved by repeated administrations, the dosing interval being related to the cell cycle time of the susceptible normal host tissue."( Increasing 1-beta-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics.
Agur, Z; Schechter, B; Tagliabue, G; Ubezio, P, 1994
)
0.29
" This dosage shortened the time it took for the reduced-size hepatic transplant labeling index to peak."( Liver regeneration after orthotopic reduced-size hepatic transplantation in the rat.
Goto, M; Hamaguchi, H; Hisama, N; Kikuchi, N; Makino, Y; Mori, K; Ogawa, M; Takata, N; Yamaguchi, Y, 1994
)
0.29
", labeling during Days 1-3) of dosing with 80 mg/kg/day phenobarbital."( Phenobarbital-induced hepatocellular proliferation: anti-bromodeoxyuridine and anti-proliferating cell nuclear antigen immunocytochemistry.
Barrass, NC; Clarke, NA; Jones, HB, 1993
)
0.53
" Thus, the most straightforward risk assessment for chloroform for this tissue would assign no increased cancer risk for dosing regimens that do not induce cytolethality and cell proliferation."( Induced cytotoxicity and cell proliferation in the hepatocarcinogenicity of chloroform in female B6C3F1 mice: comparison of administration by gavage in corn oil vs ad libitum in drinking water.
Butterworth, BE; Larson, JL; Wolf, DC, 1994
)
0.29
"Gavage dosing of the irritant, ethyl acrylate (EA), has been found to induce hyperplasia in the rat forestomach, but no signs of toxicity in the glandular stomach or in organs remote from the site of dosing."( Quantitation of an epithelial S-phase response in the rat forestomach and glandular stomach following gavage dosing with ethyl acrylate.
Frederick, CB; Gillette, DM, 1993
)
0.29
" This dosage improved the delay in the reduced-size hepatic transplant LI reaching its peak."( Effect of cyclosporine on liver regeneration after orthotopic reduced-size hepatic transplantation in the rat.
Goto, M; Hamaguchi, H; Hisama, N; Kikuchi, N; Makino, Y; Mori, K; Ogawa, M; Takata, N; Yamaguchi, Y, 1993
)
0.29
" This futile DNA repair is not required, however, since inhibition of this process by > 90% with an appropriately timed hydroxy-urea dosing regimen had no effect upon the extent of the programmed death of these cells after castration."( Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation.
Berges, RR; English, HF; Furuya, Y; Isaacs, JT; Jacks, T; Remington, L, 1993
)
0.29
" Significant DNA damage was detected up to 14 days after dosing with return to near background levels by 20 days."( Extent and persistence of streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays.
Clair, JH; DeLuca, JG; Eydelloth, RS; Jensen, RD; Kloss, MW; Kraynak, AR; Nichols, WW; Soper, KA; Storer, RD, 1995
)
0.29
" The precise timing and dosage of BrdU enable tissue kinetics studies."( Immunohistochemical detection of proliferative cells.
Mokrý, J; Nĕmecek, S, 1995
)
0.29
"Bromodeoxyuridine (BrdU), a non-radioactive thymidine analogue, was administered to 15 cattle at a dosage of 1-10 mg/kg intravenously or intraperitoneally to demonstrate S-phase cells in the tissues."( Immunohistochemical demonstration of S-phase cells by anti-bromodeoxyuridine monoclonal antibody in cattle tissues.
Isowa, K; Iwasaki, T; Masegi, T; Matsumoto, C; Sakai, H; Sato, Y; Takashima, H; Yanai, T; Yoshida, K, 1996
)
1.98
" Thus, it appears that regional chemotherapy may be applied to halogenated pyrimidines following hepatic arterial, portal venous, and alternating regional dosing routes with no additional risk of systemic toxicity."( Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions.
DeRemer, SJ; Ensmiger, WD; Knol, JA; Kuan, HY; Smith, DE; Stetson, PL; Yang, Z, 1996
)
0.29
" The dose-response curves indicate that a single event, such as an irreparable DNA break, may be sufficient to induce arrest."( p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation.
Clarkin, KC; Linke, SP; Wahl, GM, 1997
)
0.3
" Analysis of the kinetic pattern of the appearance of BrdU+ cells in bone marrow, blood, spleen, and lymph nodes over 12 weeks revealed that the dosage of BrdU initially was high enough to label the proliferating cells in the bone marrow, but then became too low, although the BrdU uptake of the rats was similar over the entire time."( Long-term oral application of 5-bromo-2-deoxyuridine does not reliably label proliferating immune cells in the LEW rat.
Beuleke, A; Dressendörfer, I; Jecker, P; Pabst, R; Westermann, J, 1997
)
0.3
" For examining the modifying effects of 'initiation' treatment of test compounds, groups of animals were fed the diets containing 1000 ppm diosmin and 1000 ppm hesperidin, and the diet containing both compounds (900 ppm diosmin and 100 ppm hesperidin) for 13 weeks, starting 7 days before the MNAN dosing and then switched to the basal diet."( Modulation of N-methyl-N-amylnitrosamine-induced rat oesophageal tumourigenesis by dietary feeding of diosmin and hesperidin, both alone and in combination.
Fukutani, K; Hara, A; Kakumoto, M; Kawabata, K; Makita, H; Mori, H; Ogawa, H; Satoh, K; Sumida, T; Tanaka, T, 1997
)
0.3
" We established a dose-response relationship between the number of fibers delivered to the parietal peritoneal lining, inflammation, and mesothelial cell proliferation induced by intraperitoneal injection of crocidolite asbestos fibers in mice."( Mesothelial cell proliferation and biopersistence of wollastonite and crocidolite asbestos fibers.
Kane, AB; Macdonald, JL, 1997
)
0.3
" Dose-response curves of PLP and PLP peptide showed maximum activities at a concentration in the picomolar range, which decreased at higher concentrations."( Proteolipid protein gene product can be secreted and exhibit biological activity during early development.
Ikenaka, K; Ivanova, A; Lees, MB; Yamada, M; Yamaguchi, Y, 1999
)
0.3
" The light microscopic appearance and collagen staining of the lungs of the dually treated rats were similar to the negative control rat lungs 2 weeks after dosing with 3-MI."( Manipulation of injury and repair of the alveolar epithelium using two pneumotoxicants: 3-methylindole and monocrotaline.
Segall, HJ; Wilson, DW; Woods, LW, 1999
)
0.3
" Thus, a reduction of p21 dosage may promote tumor progression in the presence of other oncogenic initiators."( Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model.
Cui, XS; Donehower, LA; Jones, JM; Medina, D, 1999
)
0.3
" Hepatic BrdU labeling was increased 40-fold in females (240 mg/kg/day) and 20-fold in males (140 mg/kg/day) after 4 days of dosing with chloroform."( V-Ha-ras gene expression in liver and kidney of transgenic Tg.AC mice following chemically induced tissue injury.
Delker, DA; Gollapudi, BB; Yano, BL, 1999
)
0.3
" Four days before necropsy, mice were dosed with bromodeoxyuridine (BrdU) using osmotic pumps."( Troglitazone-induced heart and adipose tissue cell proliferation in mice.
Breider, MA; de la Iglesia, FA; Gough, AW; Haskins, JR; Sobocinski, G,
)
0.39
" Our objectives were to investigate the mode of action of bladder tumor formation, evaluate the dose-response and the role of diet and to determine if the urothelial effects were reversible."( Effects of dietary dimethylarsinic acid on the urine and urothelium of rats.
Arnold, LL; Cano, M; Cohen, SM; Eldan, M; St John, M; van Gemert, M, 1999
)
0.3
" We have reported previously that 7-day dosing with DEHP induced a higher bromodeoxyuridine labeling index (LI) in binuclear octoploid (2x4N) rat hepatocytes than did DCB, suggesting that induction of DNA synthesis in 2x4N hepatocytes might represent a more substantial carcinogenic risk."( The nongenotoxic hepatocarcinogens diethylhexylphthalate and methylclofenapate induce DNA synthesis preferentially in octoploid rat hepatocytes.
Hasmall, SC; Roberts, RA,
)
0.36
"We tested the following hypotheses: (1) enterally dosed Epo is absorbed from the intestines of neonatal rats, (2) Epo acts as a trophic factor in developing small bowel, and (3) the trophic effects of Epo are dependent on the route of administration."( Erythropoietin acts as a trophic factor in neonatal rat intestine.
Christensen, RD; Dame, C; DeMarco, V; Joyce, AE; Juul, SE; Ledbetter, DJ; Zhao, Y, 2001
)
0.31
"The dose dependent effects of enterally dosed recombinant human erythropoietin (rEpo 0--1000 U/kg/day) were studied in artificially raised rat pups and compared with dam raised controls and dam raised pups given rEpo in rat milk."( Erythropoietin acts as a trophic factor in neonatal rat intestine.
Christensen, RD; Dame, C; DeMarco, V; Joyce, AE; Juul, SE; Ledbetter, DJ; Zhao, Y, 2001
)
0.31
" Thus enterally dosed rEpo has no erythropoietic effects."( Erythropoietin acts as a trophic factor in neonatal rat intestine.
Christensen, RD; Dame, C; DeMarco, V; Joyce, AE; Juul, SE; Ledbetter, DJ; Zhao, Y, 2001
)
0.31
" In this study, the dose-response analysis of genistein at the physiologically achievable concentration range between 125 and 1,000 microg/g in the diet was conducted in ovariectomized athymic nude mice implanted with MCF-7 cells."( Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice.
Allred, CD; Allred, KF; Doerge, DR; Helferich, WG; Ju, YH; Karko, KL, 2001
)
0.31
" However, the persistence of the response of the glial cells in adult brain had not been previously reported, after the excitotoxic damage caused by neonatal dosage of monosodium glutamate (MSG) to newborn rats."( Astrocytic and microglia cells reactivity induced by neonatal administration of glutamate in cerebral cortex of the adult rats.
Beas Zárate, C; García-Estrada, J; Huerta, M; Lopez-Perez, S; Luquín, S; Martínez-Contreras, A, 2002
)
0.31
" Cytotoxicity data including dose-response relations and TC(50) values were assessed in three different assays: BrdU incorporation, neutral red uptake and MTT assays."( Formaldehyde cytotoxicity in three human cell types assessed in three different assays.
Arenholt-Bindslev, D; Eiskjaer, M; Lovschall, H, 2002
)
0.31
" No papillomas or any other skin lesions were observed in age- and sex-matched VDR(+/+) mice dosed with DMBA and followed for 6 months."( Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis.
Sundberg, JP; Welsh, J; Zinser, GM, 2002
)
0.31
" Brivudin has a markedly higher anti-VZV potency than oral acyclovir, valacyclovir and famciclovir and thus offers a simpler dosing regimen."( Herpes zoster guideline of the German Dermatology Society (DDG).
Doerr, HW; Friese, K; Gross, G; Guthoff, R; Malin, JP; Pau, HW; Schöfer, H; Timm, A; Wassilew, S; Wutzler, P, 2003
)
0.32
" In addition, a time course study with constant dosage of drugs was performed."( The cell cycle distribution of cultured human retinal pigmented epithelial cells under exposure of anti-proliferative drugs.
Kao, YH; Tseng, HY; Wu, WC, 2003
)
0.32
" In a dose-response study, effects were dose-dependent, the dose of 400 mg/kg causing eight-fold elevation as compared to the control."( The mouse rasH2/BHT model as an in vivo rapid assay for lung carcinogens.
Hioki, K; Hirose, M; Kodama, Y; Kurokawa, Y; Nishikawa, A; Nomura, T; Umemura, T, 2002
)
0.31
" We show that at therapeutic dosage (or at micromolar range), flavopiridol almost completely prevents colchicine-induced apoptosis in cerebellar granule neurones."( Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis.
Bravo, R; Bruna, A; Caelles, C; Camarasa, J; Camins, A; Canudas, AM; Escubedo, E; Jiménez, A; Jorda, EG; Pallàs, M; Pubill, D; Verdaguer, E, 2003
)
0.32
"2-Methoxyestradiol (2-ME2) was reported to elicit both stimulation and inhibition of tumor angiogenesis and growth depending on the dosage used."( 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-alpha: a possible signaling pathway associated with the impact of 2-ME2 on proliferative cells.
Banerjee, S; Banerjee, SK; Banerjee, SN; Saxena, NK; Sengupta, K,
)
0.13
"Rats were injected with bromodeoxyuridine to label proliferating cells in the dentate gyrus after single/multiple electroconvulsive seizures in a dose-response study and at various time points after single electroconvulsive seizures in a time-course study."( Electroconvulsive seizures induce endothelial cell proliferation in adult rat hippocampus.
Bengzon, J; Hellsten, J; Mohapel, P; Tingström, A; Wennström, M, 2004
)
0.63
"A dose-response effect on the number of bromodeoxyuridine-labeled endothelial cells located in the granule cell layer, hilus, and molecular layer was noted, as was the case with the number of neural precursors in the subgranular zone."( Electroconvulsive seizures induce endothelial cell proliferation in adult rat hippocampus.
Bengzon, J; Hellsten, J; Mohapel, P; Tingström, A; Wennström, M, 2004
)
0.59
" In contrast, systemically administered(ie, intraperitoneally) anti-eotaxin-1 and/or anti-eotaxin-2 resulted in a significant decrease in BAL eosinophils only when the combined treatment was of a sufficiently high dosage to produce measurable concentrations in the airways."( Eotaxin-2 regulates newly produced and CD34 airway eosinophils after allergen exposure.
Johansson, AK; Lötvall, J; Rådinger, M; Sitkauskiene, B; Sjöstrand, M, 2004
)
0.32
" Finally, a dose-response study showed that progressive doses of corticosterone (0-40 mg/kg/day) in ADX rats resulted in diminished suppression of proliferation in 5-HT-depleted compared with 5-HT-intact rats."( Serotonin modulates the suppressive effects of corticosterone on proliferating progenitor cells in the dentate gyrus of the hippocampus in the adult rat.
Herbert, J; Huang, GJ, 2005
)
0.33
" We have used a model DNA containing a bulge, formed by five mismatched bases, and have observed a linear dose-response for the formation of strand breaks on the single-stranded regions of both the brominated strand and the opposite nonbrominated strand."( Interstrand cross-links: a new type of gamma-ray damage in bromodeoxyuridine-substituted DNA.
Cecchini, S; Girouard, S; Huels, MA; Hunting, DJ; Sanche, L, 2005
)
0.57
"To study the optimal dosage and timing for bromodeoxyuridine (BrdU) labeling of rat bone marrow-derived mesenchymal stem cells (MSCs) in vitro."( [In vitro bromodeoxyuridine labeling of rat bone marrow-derived mesenchymal stem cells].
Feng, SW; Huang, W; Li, Z; Liu, TY; Yao, XL; Zhang, C, 2005
)
0.99
" Dividing myeloid progenitors in the marrow of rabbits were labeled with a pulse dosage of intravenous BrdU."( Flow cytometric method for enumeration and characterization of newly released polymorphonuclear leukocytes from the bone marrow using 5'-bromo-2'-deoxyuridine.
Goto, Y; Hogg, JC; Shih, CH; van Eeden, SF; Whalen, BA, 2005
)
0.33
" dosing of a novel MCHR1 antagonist, N-[3-(1-{[4-(3,4-difluorophenoxy)-phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847), in three mouse models predictive of antidepressant/anxiolytic-like activity: novelty suppressed feeding (NSF) in 129S6/SvEvTac mice and light/dark paradigm (L/D) and forced swim test (FST) in BALB/cJ mice."( Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocam
Craig, DA; David, DJ; Dong, D; Gerald, CP; Hegde, LG; Hen, R; Holick, KA; Klemenhagen, KC; Marzabadi, MR; Mendez, I; Ping, XI; Santarelli, L; Saxe, MD; Swanson, CJ; Zhong, H, 2007
)
0.34
" Saturation of propylene conversion to propylene oxide was apparent from the adduct dose-response curves."( Evaluation of effects from repeated inhalation exposure of F344 rats to high concentrations of propylene.
Banton, MI; Bogdanffy, MS; Donner, EM; Harkema, JR; Li, Y; Malley, LA; Pottenger, LH; Swenberg, JA; Upton, PB; Walker, VE, 2007
)
0.34
" Slugs were dosed with a mixture of cadmium and kerosene in the food for 27 days."( Digestive cell turnover in digestive gland epithelium of slugs experimentally exposed to a mixture of cadmium and kerosene.
Cancio, I; Marigómez, I; Soto, M; Zaldibar, B, 2007
)
0.34
"C6 rat glioma cells were treated with suramin at doses of 175 and 250 microM, and also with an increasing dosage for 96 hours."( The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells.
Akev, N; Bilir, A; Erguven, M; Karabulut, E; Ozdemir, A, 2008
)
0.35
" Next, by exploiting a Pbx1/Pbx2 loss-of-function mouse, we show that decreasing Pbx2 dosage in the absence of Pbx1 affects axial development more severely than single loss of Pbx1."( Pbx1/Pbx2 govern axial skeletal development by controlling Polycomb and Hox in mesoderm and Pax1/Pax9 in sclerotome.
Asciutti, S; Capellini, TD; Di Giacomo, G; Di Gregorio, A; Kugler, JE; Selleri, L; Zewdu, R, 2008
)
0.35
"The present study compared multiple BrdU dosing and loading protocols to determine a dosing strategy that produced the best signal to noise ratio."( Flow cytometric analysis of BrdU incorporation as a high-throughput method for measuring adult neurogenesis in the mouse.
Balu, DT; Bender, CN; Dwyer, JM; Hill, TE; Ho, N; Hodes, GE; Hughes, ZA; Lucki, I; Rahman, Z; Ring, RH; Rosenzweig-Lipson, S; Schechter, LE,
)
0.13
" Fetuses dosed on G 14 exhibited an increased frequency of YFP+ neurons across cortex."( Lability of neuronal lineage decisions is revealed by acute exposures to ethanol.
Hu, H; Miller, MW, 2009
)
0.35
"To investigate the optimal dosage and timing for 5-bromodeoxyuridine (BrdU) labeling of endothelial progenitor cells (EPCs) from rat circulating blood."( [Study of 5-bromodeoxyuridine labeling of endothelial progenitor cells from the circulating blood from tooth movement rat].
Liu, C; Liu, JZ; Miao, LY; Sun, XH, 2009
)
0.98
" The dosage and duration of BrdU appear critical, since exposure to low doses did not result in a robust label using this marker for proliferation [Zhao et al."( Bromodeoxyuridine infused into the cerebral ventricle of adult mice labels nigral neurons under physiological conditions--a method to detect newborn nerve cells in regions with a low rate of neurogenesis.
Janson Lang, AM; Zhao, M, 2009
)
1.8
" We analyzed whether a series of ECSs could induce changes in the dentate gyrus in a dose-response fashion."( Effects of repeated electroconvulsive seizure on cell proliferation in the rat hippocampus.
Arai, H; Ito, M; Liu, J; Matsubara, Y; Nakamura, K; Namba, T; Seki, T; Suzuki, T, 2010
)
0.36
" Additionally, a subset of mice was dosed once daily for 1 week (10 mg/kg)."( Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.
Denton, CL; Gustafson, DL, 2011
)
0.37
" In large meat-production animals, however, the traditional in vivo proliferation assay may be less realistic because it requires intra-peritoneal (ip) injection of huge dosage of mutagenic nucleosides, (3)H-labeled thymidine or bromodeoxyuridine (BrdU), at each age-time of sacrifice."( In vitro measurement of post-natal changes in proliferating satellite cell frequency during rat muscle growth.
Do, MK; Hara, M; Hattori, A; Ikeuchi, Y; Mizunoya, W; Nishimura, T; Sakata, T; Sato, A; Suzuki, T; Takaishi, H; Tatsumi, R, 2010
)
0.54
" Our experimental approach was based on quantitative analysis of EGFR gene dosage in vitro both at DNA and mRNA level."( Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.
Bieńkowski, M; Grešner, SM; Hułas-Bigoszewska, K; Ironside, JW; Jaskólski, DJ; Kolasa, M; Kulczycka-Wojdala, D; Liberski, PP; Papierz, W; Piaskowski, S; Rieske, P; Stawski, R; Stoczyńska-Fidelus, E; Witusik-Perkowska, M; Zakrzewska, M; Zakrzewski, K, 2011
)
0.37
" Cisplatin dose-response curves were constructed in MCF7 and MDA-MB-231 transfected with four siRNA corresponding to each of these YB-1 interactors to identify proteins significantly affecting cisplatin sensitivity upon gene silencing."( An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
Chow, D; Garand, C; Guay, D; Langlois, M; Lebel, M; Perreault, E; Sereduk, C; Tsofack, SP; Yin, HH, 2011
)
0.37
"The dose-response of residual γH2AX foci is highly dependent on tumour cell oxygenation in well perfused areas."( Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours.
Baumann, M; Eicheler, W; Krause, M; Menegakis, A; Thames, HD; Yaromina, A, 2011
)
0.37
" These defects were more severe with decreasing gene dosage of Lmx1a and Lmx1b or observed only when all four copies of Lmx1a and Lmx1b genes were inactivated."( Lmx1a and lmx1b function cooperatively to regulate proliferation, specification, and differentiation of midbrain dopaminergic progenitors.
Ang, SL; Claxton, S; Johnson, RL; Levesque, M; Yan, CH, 2011
)
0.37
" Treatment of cerebellar granule neuron cultures with both GCs significantly reduced the percentage of proliferating-cell nuclear antigen (PCNA) positive neurons and increased NeuN positive neurons, with similar dose-response relationship as in vivo."( Glucocorticoids dexamethasone and hydrocortisone inhibit proliferation and accelerate maturation of chicken cerebellar granule neurons.
Aden, P; Goverud, IL; Liestøl, K; Løberg, EM; Lømo, J; Mæhlen, J; Paulsen, RE, 2011
)
0.37
" Here, we show that two commonly used post-operative buprenorphine dosing regimes significantly inhibit the proliferation of doublecortin-positive neuroblasts but not other hippocampal stem and progenitor cell populations in adult mice."( The opiate analgesic buprenorphine decreases proliferation of adult hippocampal neuroblasts and increases survival of their progeny.
Bennett, SA; Desroches, R; Pettit, AS, 2012
)
0.38
" Furthermore, the superior pharmacokinetics and more convenient dosing regimens with the use of valaciclovir and famciclovir clearly make them the preferred treatment option."( Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials.
de Kock, J; McDonald, EM; Ram, FS, 2012
)
0.38
" Comparable dose-response curves and IC50 values (57-63 μM, 24h treatment) were obtained using the MTT reduction, crystal violet and BrdU assays."( Cytotoxic effects of cadmium in mammary epithelial cells: protective role of the macrocycle [15]pyN5.
Cabral, MF; Castro, M; Cipriano, M; Costa, J; Fernandes, AS; Gonçalves, S; Guerreiro, PS; Marques, J; Miranda, J; Oliveira, NG, 2012
)
0.38
"018); this effect tended to increase with antidepressant dosage (r = 0."( Increased nuclear Olig1-expression in the pregenual anterior cingulate white matter of patients with major depression: a regenerative attempt to compensate oligodendrocyte loss?
Bernstein, HG; Bogerts, B; Dobrowolny, H; Gos, T; Keilhoff, G; Mawrin, C; Mosebach, J; Müller, S; Schiltz, K; Schoeneck, L; Schroeter, ML; Steiner, J, 2013
)
0.39
" The purpose of this study was to perform a dose-response study of Tβ4 to determine the optimal dose of neurological improvement in a rat model of embolic stroke."( A dose-response study of thymosin β4 for the treatment of acute stroke.
Cheung, WL; Chopp, M; Cui, Y; Lu, M; Morris, DC; Zhang, L; Zhang, ZG, 2014
)
0.4
" It showed that exposure to propofol on P7 decreased hippocampal cell proliferation as indicated by BrdU and Sox2 immunostaining at P8 in propofol treatment at the dosage of 60 mg/kg but not at the dosage of 30 mg/kg."( Propofol Administration During Early Postnatal Life Suppresses Hippocampal Neurogenesis.
Bao, X; Chen, X; Du, Z; Fan, X; Huang, J; Jing, S; Li, H; Yang, T, 2016
)
0.43
" The results indicate that the commonly used dosage of BrdU in birds has no long-term effects on subsequent cell divisions and neuronal recruitment."( The cell birth marker BrdU does not affect recruitment of subsequent cell divisions in the adult avian brain.
Ayali, A; Barnea, A; Cattan, A, 2015
)
0.42
" 32 male Wistar rats were injected with a double dosage of 15 ml/kg busulfan with 14 days interval."( Effect of human recombinant granulocyte colony-stimulating factor on rat busulfan-induced testis injury.
Amidi, F; Khanlarkhani, N; Mortezaee, K; Najafi, A; Naji, M; Pasbakhsh, P; Sobhani, A; Zendedel, A, 2016
)
0.43
" Further, Metoprolol doses of 25mg for geriatric women and 50mg for geriatric men resulted in an equivalent AUC to a healthy young males dosed with a 100mg tablet."(
Aguirre, MV; Albert, PS; Alotti, N; Bao, W; Basolo, F; Bottici, V; Brandan, NC; Cappagli, V; Casella, F; Ciampi, R; Colavita, JP; Elisei, R; Espada, JD; Eugene, AR; He, D; Hinkle, SN; Hu, Z; Kalish, F; Lerman, DA; Materazzi, G; Matrone, A; Mendola, P; Piaggi, P; Prasad, S; Rodríguez, JP; Romei, C; Stevenson, DK; Stoyanoff, TR; Tacito, A; Todaro, JS; Torregrossa, L; Torres, AM; Tsai, MY; Ugolini, C; Valerio, L; Viola, D; Vitti, P; Wang, W; Wong, RJ; Xiao, J; Xie, M; Zhang, C; Zhang, H; Zhao, H; Zhu, Y, 2016
)
0.43
" We conclude that thyroid cells exposed to Roundup present a nonmonotonic dual dose-response curve."( Alternation between toxic and proliferative effects of Roundup® on human thyroid cells at different concentrations.
Bufalo, NE; Chiamolera, MI; Dal' Bó, IF; Máximo, V; Nascimento, M; Peres, KC; Rabi, LT; Teixeira, ES; Ward, LS, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrimidine 2'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (46)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interleukin 8Homo sapiens (human)Potency53.08040.047349.480674.9780AID651758
pregnane X receptorRattus norvegicus (Norway rat)Potency39.81070.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency12.91980.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID493106
TDP1 proteinHomo sapiens (human)Potency11.75460.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency50.11870.000221.22318,912.5098AID588515
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency5.76780.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency29.84930.000417.946075.1148AID1346784
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency1.24970.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency1.89850.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency57.66720.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.67870.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency12.38340.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency40.92260.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078; AID743080; AID743091
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency6.30960.707936.904389.1251AID504333
arylsulfatase AHomo sapiens (human)Potency30.13131.069113.955137.9330AID720538
IDH1Homo sapiens (human)Potency0.58050.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.23870.035520.977089.1251AID504332
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency4.46680.10009.191631.6228AID1346983
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency31.62280.316212.443531.6228AID902
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency8.19950.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency43.93810.000323.4451159.6830AID743066
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency13.09180.00378.618923.2809AID2668
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency2.92070.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency5.99530.005612.367736.1254AID624032; AID624044
survival motor neuron protein isoform dHomo sapiens (human)Potency12.06270.125912.234435.4813AID1458
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency14.12540.00106.000935.4813AID944
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency61.85060.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency61.85060.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency7.49780.026622.448266.8242AID651802
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency28.18380.009610.525035.4813AID1479145
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency13.72820.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency13.33320.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase, cytosolicHomo sapiens (human)Ki15.03000.09001.52137.0000AID210689; AID210691
Thymidylate kinaseMycobacterium tuberculosis H37RvKi5.00004.50008.500010.0000AID408386
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear hormone receptor family member daf-12Caenorhabditis elegansEC50 (µMol)67.52604.23604.23604.2360AID743038
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine phosphorylaseHomo sapiens (human)Km121.00000.16000.16000.1600AID211066
Thymidine kinaseVaccinia virus WRKm30.00004.30004.30004.3000AID324741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processThymidine kinase, cytosolicHomo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine metabolic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
protein homotetramerizationThymidine kinase, cytosolicHomo sapiens (human)
DNA synthesis involved in mitotic DNA replicationThymidine kinase, cytosolicHomo sapiens (human)
mitochondrial genome maintenanceThymidine phosphorylaseHomo sapiens (human)
angiogenesisThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleobase metabolic processThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleoside metabolic processThymidine phosphorylaseHomo sapiens (human)
chemotaxisThymidine phosphorylaseHomo sapiens (human)
signal transductionThymidine phosphorylaseHomo sapiens (human)
cell differentiationThymidine phosphorylaseHomo sapiens (human)
regulation of myelinationThymidine phosphorylaseHomo sapiens (human)
dTMP catabolic processThymidine phosphorylaseHomo sapiens (human)
regulation of transmission of nerve impulseThymidine phosphorylaseHomo sapiens (human)
regulation of gastric motilityThymidine phosphorylaseHomo sapiens (human)
dTDP biosynthetic processThymidylate kinaseHomo sapiens (human)
dTTP biosynthetic processThymidylate kinaseHomo sapiens (human)
response to estrogenThymidylate kinaseHomo sapiens (human)
myoblast differentiationThymidylate kinaseHomo sapiens (human)
thymidine biosynthetic processThymidylate kinaseHomo sapiens (human)
response to cadmium ionThymidylate kinaseHomo sapiens (human)
nucleoside monophosphate phosphorylationThymidylate kinaseHomo sapiens (human)
cellular response to growth factor stimulusThymidylate kinaseHomo sapiens (human)
dUDP biosynthetic processThymidylate kinaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
thymidine kinase activityThymidine kinase, cytosolicHomo sapiens (human)
protein bindingThymidine kinase, cytosolicHomo sapiens (human)
ATP bindingThymidine kinase, cytosolicHomo sapiens (human)
zinc ion bindingThymidine kinase, cytosolicHomo sapiens (human)
identical protein bindingThymidine kinase, cytosolicHomo sapiens (human)
1,4-alpha-oligoglucan phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein bindingThymidine phosphorylaseHomo sapiens (human)
growth factor activityThymidine phosphorylaseHomo sapiens (human)
thymidine phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein homodimerization activityThymidine phosphorylaseHomo sapiens (human)
thymidylate kinase activityThymidylate kinaseHomo sapiens (human)
ATP bindingThymidylate kinaseHomo sapiens (human)
nucleoside diphosphate kinase activityThymidylate kinaseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
nucleusThymidine kinase, cytosolicHomo sapiens (human)
cytosolThymidine kinase, cytosolicHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytosolThymidine phosphorylaseHomo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
mitochondrial matrixThymidylate kinaseHomo sapiens (human)
cytosolThymidylate kinaseHomo sapiens (human)
mitochondrionThymidylate kinaseHomo sapiens (human)
nucleusThymidylate kinaseHomo sapiens (human)
cytoplasmThymidylate kinaseHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (132)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID167902Minimal inhibitory concentration against HSV-1 (F)-induced cytopathogenicity by 50% in rabbit kidney cell cultures1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.
AID98529Evaluation of antitumor activity against mutant murine leukemia L1210 cells1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID167908Minimal inhibitory concentration against vaccinia virus-induced cytopathogenicity by 50% in rabbit kidney cell cultures1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.
AID84605Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 2.1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID1135815Competitive inhibition of HSV-1 pyrimidine deoxythymidine kinase using 2-[14C]deoxythymidine as substrate1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID408386Inhibition of Mycobacterium tuberculosis recombinant TMPK2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity.
AID211066Michaelis-Menten constant (Km) against horse liver thymidine phosphorylase1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID167906Minimal inhibitory concentration against HSV-2 (G)-induced cytopathogenicity by 50% in rabbit kidney cell cultures1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.
AID210692Relative phosphorylation rate against HSV-2(333) thymidine kinase1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID87826Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain 196.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID1135806Antiviral activity against HSV1 CL101 infected in African green monkey Vero cells assessed as inhibition of plaque formation at 10 uM after 40 hrs relative to control1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID139991Inhibition constant for influx competition with [6-3H]thymidine in mouse erythrocytes1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and tumor uptake of 5-82Br- and 5-131I-labeled 5-halo-1-(2-fluoro-2-deoxy-beta-D-ribofuranosyl)uracils.
AID324742Ratio of Vmax to Km for Vaccinia virus WR thymidine kinase2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID87507Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain KOS.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID84609Concentration required to inhibit HSV type 2 strain MS induced cytopathogenic affects by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID167911Minimal inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology of rabbit kidney cell cultures1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID324741Activity of Vaccinia virus WR thymidine kinase assessed as ATP utilization by luciferase-based assay2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID167907Minimal inhibitory concentration against HSV-2 (Lyons)-induced cytopathogenicity by 50% in rabbit kidney cell cultures1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.
AID408387Inhibition of human TMPK2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity.
AID87827Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain G1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID167904Minimal inhibitory concentration against HSV-1 (McIntyre)-induced cytopathogenicity by 50% in rabbit kidney cell cultures1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.
AID81372Minimum concentration not causing a microscopically detectable cytotoxic alteration of normal human embryonic lung fibroblast (HELF) morphology1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID85701In vitro antiviral activity in secondary cultures of rabbit kidney cells infected with HSV type 1 strain 3771984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID324743Activity of human thymidine kinase 1 assessed as ATP utilization by luciferase-based assay2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID218132Evaluation of antiviral activity against Vaccinia virus1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID167909Minimal inhibitory concentration against vesicular stomatitis virus-induced cytopathogenicity by 50% in rabbit kidney cell cultures1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.
AID521209Antiproliferative activity against mouse astrocyte cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID280941Cytotoxicity against mouse L1210/0 cells after 48 hrs2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID1135478Antiviral activity against Vaccinia virus infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID98532Evaluation of cytostatic activity by using antitumor assays against murine leukemia L1210 cells1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID408392Selectivity index, ratio of Ki for human TMPK to Ki for Mycobacterium tuberculosis recombinant TMPK2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID51924Effect on cross resistance of chinese hamster cells resistant to Actinomycin D.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID87196Antiherpes activity was tested as percent of control of plaque-formation against HSV-1 (KOS) virus by 100 uM of the compound1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID210689Binding affinity against HSV-1(KOS) thymidine kinase1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID1135811Antimicrobial activity against Streptococcus faecium assessed as growth inhibition at 400 uM after 15 to 17 hrs by turbidity assay in presence of 7 uM deoxythymidine1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID83716Ability to reduce plaque formation of herpes simplex virus type 1 (HSV-1) by 50% in human embryonic lung fibroblast (HELF) cell cultures1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID1135481Antiviral activity against Herpes simplex virus 1 infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID324744Ratio of Vmax to Km for human thymidine kinase 12007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID99530In vitro growth inhibition of L5178Y-Parental murine leukemia cells2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID99532In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]-Thd.2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID55154Incorporation of compound into DNA of human and mammalian cells, by replacing thymidine1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and tumor uptake of 5-82Br- and 5-131I-labeled 5-halo-1-(2-fluoro-2-deoxy-beta-D-ribofuranosyl)uracils.
AID87828Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain Lyons1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID87323Antiherpes activity was tested as percent of control of plaque-formation against HSV-2 (CEU-G) virus by 100 uM of the compound1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID521208Antiproliferative activity against mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1135817Retention time of the compound by liquid chromatography1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID87321Antiherpes activity was tested as percent of control of plaque-formation against HSV-2 (333) virus by 100 uM of the compound1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID167903Minimal inhibitory concentration against HSV-1 (KOS)-induced cytopathogenicity by 50% in rabbit kidney cell cultures1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.
AID85567Concentration required to inhibit HSV type 1 strain 377 induced cytopathogenic affects by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID210690Relative phosphorylation rate against HSV-1(KOS) thymidine kinase1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID221339Evaluation for antitumor activity against human lymphoblast Raji cells1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID1135480Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID232840Ratio of Vmax to that of dThd (Vmax = 0.14)1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID408388Antimicrobial activity against Mycobacterium bovis BCG 1173P2 after 8 days2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity.
AID87508Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain McIntyre1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID210691Binding affinity against HSV-2(333) enzyme thymidine kinase1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
AID167905Minimal inhibitory concentration against HSV-2 (196)-induced cytopathogenicity by 50% in rabbit kidney cell cultures1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
5-Quinone derivatives of 2'-deoxyuridine 5'-phosphate: inhibition and inactivation of thymidylate synthase, antitumor cell, and antiviral studies.
AID85559Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 1.1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID216539Evaluation of antiviral activity against Vesicular stomatitis virus.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID220992Evaluation of antitumor activity against thymidine kinase deficient Raji cell line1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID99531In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]Leu.2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID84756In vitro antiviral activity in secondary cultures of rabbit kidney cells infected with HSV type 2 strain MS1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID1135812Antimicrobial activity against Streptococcus faecium assessed as growth inhibition at 400 uM after 15 to 17 hrs by turbidity assay in presence of 4.53 nM folic acid1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID84950Ability to reduce plaque formation of herpes simplex virus type 2 (HSV-2) by 50% in human embryonic lung fibroblast (HELF) cell cultures1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID99533In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
5-Substituted N(4)-hydroxy-2'-deoxycytidines and their 5'-monophosphates: synthesis, conformation, interaction with tumor thymidylate synthase, and in vitro antitumor activity.
AID1135479Antiviral activity against Herpes simplex virus 1 infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID408394Cytotoxicity against african green monkey Vero cells by MTT assay at 400 ug/ml after 72 hrs2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity.
AID87506Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain F1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12,732)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903472 (27.27)18.7374
1990's2798 (21.98)18.2507
2000's4271 (33.55)29.6817
2010's1984 (15.58)24.3611
2020's207 (1.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.31 (24.57)
Research Supply Index9.49 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index99.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials71 (0.54%)5.53%
Reviews260 (1.98%)6.00%
Case Studies94 (0.71%)4.05%
Observational0 (0.00%)0.25%
Other12,739 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Cell Kinetic Study of Bromodeoxyuridine (BrdU) in Prostate Cancer [NCT00003832]Phase 275 participants (Actual)Interventional1999-07-31Completed
Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha [NCT00003405]Phase 20 participants (Actual)Interventional1998-04-30Withdrawn(stopped due to No enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]